Analogue provisions

Analogue provisions are clauses in drug law that extend control to compounds structurally or pharmacologically similar to a scheduled substance, without those compounds being named in statute. The legal object they create is conditional: a substance falls under the same restrictions as its parent compound once it meets the similarity test the law specifies.

The term covers several distinct instruments. In the United States, the primary federal instrument is the Controlled Substances Analogue Enforcement Act of 1986, embedded in the Controlled Substances Act. Canada's Controlled Drugs and Substances Act and several Australian state drug laws contain comparable provisions, each with its own test and scope.

What it means in practice

Under the US Federal Analogue Act, a substance is treated as a Schedule I controlled substance if it is substantially similar in chemical structure or pharmacological effect to a Schedule I or II substance — and is intended for human consumption. That intent element is assessed from labelling, marketing, and surrounding context. A regulatory scheduling action is not required; the classification takes effect the moment both criteria are met.

Because the statute does not define substantially similar with numerical precision, what qualifies as an analogue is settled case by case, typically before a jury in criminal proceedings. A defendant may argue the compound falls outside the test; the prosecution must prove it meets it. This structure has produced inconsistent outcomes across cases involving novel psychoactive compounds.

How jurisdictions vary

Analogue frameworks differ substantially by country. The US intent-for-human-consumption requirement is not universal — some jurisdictions extend control regardless of stated purpose.

The United Kingdom moved away from the analogue model with the Psychoactive Substances Act 2016, which banned all substances capable of producing psychoactive effects except a fixed list of exemptions, bypassing case-by-case assessment. Germany, the Netherlands, and most EU member states use positive-list scheduling: a novel compound remains unscheduled until a dedicated regulatory decision places it.

A compound that falls under US analogue provisions may therefore remain entirely unscheduled in another jurisdiction — or may face an outright ban under a different legal instrument altogether.

What is contested

The analogue framework rests on the assumption that structural similarity reliably predicts pharmacological effect and risk profile — an assumption that does not always hold in practice. Two closely related compounds may bind to different receptors, produce qualitatively different effects, or carry different toxicity characteristics.

Courts have acknowledged this tension without resolving it consistently. Expert witnesses in analogue prosecutions regularly disagree about whether a compound is substantially similar, reflecting genuine scientific uncertainty. The classification assigns the similarity question to a jury; pharmacological assessment of novel compounds typically requires specialist receptor-binding and preclinical data that may not exist at the time of prosecution.

Scope and currency

This entry describes analogue provisions in general terms as of August 2026. It is not legal advice and does not describe the law in any particular jurisdiction. Whether a specific compound qualifies as an analogue depends on the jurisdiction, the applicable test, and — in criminal proceedings — the facts of the case.

For jurisdiction-specific, dated, and sourced information, consult the legal status section on each substance's page — that section carries its own jurisdiction, date, and source, and is the value to rely on.